Mark Altmeyer is a seasoned biopharma executive with more than 35 years of leadership experience across large pharma and high-growth biotech companies focusing on multiple therapeutic areas.

He was Founder and CEO of Arvelle Therapeutics, where he led the company’s transatlantic build-out, secured $200 million in financing and successfully completed a $1 billion acquisition by Angelini Pharma within two years. His earlier roles include CCO at Axovant, as well as senior commercial and general management positions at Bristol-Myers Squibb and Otsuka. At Otsuka, he led the launch and expansion of Abilify to become the top selling pharmaceutical product in the U.S. in 2013, increasing revenue to over $7 billion.

In addition to his executive experience, Mark adds extensive board-level leadership across the biotech lifecycle, from early-stage development through late-stage growth and exit. He currently serves as Chairman of AM-Pharma and Calluna Pharma and holds non-executive or independent director roles at several public and private life sciences companies. From 2016 to 2018, Mark served as an Independent Director at Myovant Sciences, which was subsequently acquired by Sumitomo Pharma in a transaction valued at approximately $3 billion.

Mark holds a BA from Middlebury College and an MBA from Harvard University. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings.